Uncategorized

Neurocrine will pay $2.9B for Soleno and its Prader-Willi medicine

Published

24 hours ago

on

April 6, 2026

By

Temp User

Neurocrine Biosciences is joining the M&A bonanza with a $2.9 billion takeover of profitable rare disease drugmaker Soleno Therapeutics.

Neurocrine will pay $53 per share, a 34% premium to its last closing price, the companies …

Related Topics:

Leave a Reply

Uncategorized9 years ago

These ’90s fashion trends are making a comeback in 2017
Contributors9 years ago

The final 6 ‘Game of Thrones’ episodes might feel like a full season
Uncategorized9 years ago

According to Dior Couture, this taboo fashion accessory is back
Uncategorized9 years ago

The old and New Edition cast comes together to perform
Uncategorized9 years ago

Phillies’ Aaron Altherr makes mind-boggling barehanded play
Uncategorized9 years ago

Uber and Lyft are finally available in all of New York State

Exit mobile version